Structure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy Recommendation
BMO Capital analyst Evan Seigerman has reiterated their bullish stance on GPCR stock, giving a Buy rating on November 5. Evan Seigerman has ...
Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
BioSpace3d
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
AbbVie shares tumble after schizophrenia drug disappoints
US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms ...
NBC Los Angeles4d
Amgen says no concerns around weight loss drug's bone density data after stock falls
BMO analyst Evan Seigerman wrote in a note Tuesday that "We'd be cautious about making an overarching judgment on the safety profile of MariTide with this data." He added that "we'd be more ...
NBC Washington4d
Amgen stock falls as analysts mull over weight loss drug's bone density data
BMO analyst Evan Seigerman wrote in a note Tuesday that "We'd be cautious about making an overarching judgment on the safety profile of MariTide with this data." He added that "we'd be more ...